Bevacizumab biosimilar (CTTQ Pharma) |
TQ-B2302 |
Phase 3 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Ovarian Neoplasms; Glioblastoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
Ranibizumab biosimilar (Qilu Pharmaceutical) |
BCD-300; QL-1205 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd, Biocnd |
Macular Degeneration |
Details
|
Varisacumab |
R-84; GNR-011; AT-001-IBCG |
Phase 3 Clinical |
Peregrine, Ut Southwestern Medical Center |
Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Ethyl acetate extract |
ALS-L1023 |
Phase 2 Clinical |
Angiolab Inc |
Non-alcoholic Fatty Liver Disease; Obesity; Macular Degeneration |
Details
|
RC-28 |
RC28-E; RC-28-E; RC-28 |
Phase 2 Clinical |
Rc Biotechnologies Ltd |
Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy |
Details
|
MP-0250 |
MP-0250 |
Phase 2 Clinical |
Molecular Partners |
Neoplasms; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung |
Details
|
Bevacizumab biosimilar (Shanghai Henlius Biotech) |
HLX-04 |
Phase 3 Clinical |
Shanghai Henlius Biotech Co Ltd |
Carcinoma; Conjunctivitis, Bacterial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
Bevacizumab biosimilar (Reliance Life Sciences) |
R-TPR-023 |
Phase 3 Clinical |
Reliance Life Sciences |
Colorectal Neoplasms |
Details
|
Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) |
HD-204 |
Phase 3 Clinical |
Hanwha Biologics |
Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Ranibizumab biosimilar (Xbrane) |
|
Phase 3 Clinical |
Xbrane Biopharma |
Macular Degeneration |
Details
|
Ranibizumab biosimilar (Pfenex) |
PF-582 |
Phase 2 Clinical |
Pfenex |
Macular Degeneration |
Details
|
Ranibizumab biosimilar (Samsung Bioepis) |
SB-11 |
Phase 3 Clinical |
Samsung Bioepis |
Macular Degeneration |
Details
|
Ranibizumab biosimilar (Reliance Life Sciences Group) |
R-TPR-024 |
Phase 3 Clinical |
Reliance Life Sciences |
Macular Degeneration |
Details
|
Intravitreal ranibizumab (Sultan Qaboos University) |
|
Phase 2 Clinical |
Sultan Qaboos University |
Retinal Dysplasia |
Details
|
ASC-06 |
ALN-VSP; ALN-VSP01; ALN-VSP02; ASC-06 |
Phase 1 Clinical |
Alnylam Pharmaceuticals Inc |
Liver Neoplasms; Neoplasms |
Details
|
Aflibercept biosimilar (Sam Chun Dang Pharm) |
SCD-411 |
|
Sam Chun Dang Pharm Co Ltd |
|
Details
|
Dilpacimab |
ABT-165; DVD-Ig ABT-165 |
Phase 2 Clinical |
Abbvie Inc |
Neoplasms; Colorectal Neoplasms |
Details
|
Bevacizumab biosimilar (Jiangsu Hengrui Medicine) |
BP-102 |
Phase 2 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Ranibizumab biosimilar (Shanghai United Cell Biotechnology) |
|
Phase 1 Clinical |
Shanghai United Cell Biotechnology Co Ltd |
Macular Edema |
Details
|
Aflibercept biosimilar (CinnaGen)(阿柏西普生物类似药(CinnaGen)) |
|
Phase 3 Clinical |
Cinnagen |
Macular Degeneration |
Details
|
Ranibizumab biosimilar (Senju) |
GBS-007 |
Phase 3 Clinical |
Senju Pharmaceutical Co Ltd |
Macular Degeneration |
Details
|
Aflibercept biosimilar (Qilu Pharmaceutical) |
QL-1207 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Macular Edema; Diabetic macular oedema; Macular Degeneration |
Details
|
CLS-1002 |
CLS-1002 |
Phase 1 Clinical |
Clearside Biomedical |
Macular Degeneration |
Details
|
Aflibercept biosimilar (Amgen) |
|
Phase 2 Clinical |
Amgen Inc |
Macular Degeneration |
Details
|
LMG-324 |
LMG-324 |
Phase 2 Clinical |
Alcon |
Macular Degeneration |
Details
|
TAB-008 |
TAB-008; TOT-102 |
Phase 3 Clinical |
Tot Biopharm Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
Vanucizumab |
RG-7221; RO-5520985; B800Z06O8K (UNII code) |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Neoplasms; Colorectal Neoplasms |
Details
|
Bevacizumab biosimilar (Celltrion) |
CT-16; CTP-16 |
Phase 3 Clinical |
Celltrion |
Adenocarcinoma of Lung; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
LHA-510 |
LHA-510 |
Phase 2 Clinical |
Alcon |
Macular Degeneration |
Details
|
Bevacizumab biosimilar (Synermore Biologics) |
SYN-050 |
Phase 1 Clinical |
Lonn Ryonn Pharma Ltd, Xingmeng Biotechnology (Beijing) Co Ltd |
Neoplasms |
Details
|
Aflibercept biosimilar (Mabwell) |
9MW0813 |
Phase 1 Clinical |
|
Diabetic macular oedema |
Details
|
Eylea Biosimilar (Alteogen) |
ALT-L9 |
Phase 1 Clinical |
Alteogen, Kissei Pharmaceutical |
Macular Degeneration |
Details
|
AZD-8601 |
AZD-8601; mRNA-AZD-8601 |
Phase 2 Clinical |
Astrazeneca Pharmaceutical Co Ltd, Modernatx |
Heart Failure |
Details
|
Bevacizumab biosimilar (mAbixience) |
MB02; BEVZ-92 |
Phase 1 Clinical |
Mabxience |
Rectal Neoplasms; Colorectal Neoplasms |
Details
|
Bevacizumab biosimilar (Beijing Mabworks Biotech) |
MIL-60 |
Phase 3 Clinical |
Institute Of Basic Medicine, Chinese Academy Of Medical Sciences, Beijing Mabworks Biotech Co Ltd |
Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BI-695502 |
BI-695502 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Brain Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Bevacizumab biosimilar (Eastern Biotech) |
JY-028 |
Phase 1 Clinical |
Beijing Oriental 100 Tai Biotechnology Co Ltd |
Wet Macular Degeneration; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Bevacizumab biosimilar (Oncobiologics) |
ONS-1045; ONS-5010 |
Phase 3 Clinical |
Outlook Therapeutics |
Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration |
Details
|
Aflibercept biosimilar (Samsung Bioepis) |
SB-15 |
Phase 3 Clinical |
Samsung Bioepis |
Macular Degeneration |
Details
|
OB-318 |
OB-318 |
Phase 1 Clinical |
Oneness Biotech |
Neoplasms; Carcinoma, Hepatocellular |
Details
|
Bevacizumab biosimilar (AryoGen Biopharma) |
|
Phase 3 Clinical |
Aryogen Biopharma |
Colorectal Neoplasms |
Details
|
Bevacizumab biosimilar (Hualan Biological Engineering) |
WBP-264 |
Phase 3 Clinical |
Hualan Genetic Engineering Co Ltd |
Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Bevacizumab biosimilar (JHL Biotech) |
JHL-1149 |
Phase 1 Clinical |
Jhl Biotech |
Ovarian Neoplasms; Colorectal Neoplasms; Lung Neoplasms |
Details
|
Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) |
|
Phase 1 Clinical |
Pepscan Systems |
Colorectal Neoplasms |
Details
|
Aflibercept biosimilar (Momenta/Mylan) |
M-710; MYL-1701P |
Phase 3 Clinical |
Mylan, Momenta |
Diabetic macular oedema |
Details
|
PTC-299 |
PTC-299 |
Phase 3 Clinical |
Ptc Therapeutics Inc |
Esophageal Neoplasms; Pneumonia; Neurofibromatoses; Coronavirus Disease 2019 (COVID-19); Neurofibromatosis 2; Breast Neoplasms; Coronavirus Infections; Leukemia, Myeloid, Acute; Sarcoma, Kaposi |
Details
|
Aflibercept/Nesvacumab |
REGN 910-3 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Diabetic macular oedema; Macular Degeneration |
Details
|
Bevacizumab biosimilar (Alphamab/R-Pharm) |
RPH-001 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd, R-Pharm |
Colorectal Neoplasms |
Details
|
Ranibizumab biosimilar (CJSC Generium) |
GNR-067 |
Phase 1 Clinical |
Cjsc Generium |
Macular Degeneration |
Details
|
Ranibizumab biosimilar (Formycon/Bioeq) |
FYB-201 |
Phase 3 Clinical |
Formycon |
Macular Degeneration |
Details
|
Bevacizumab biosimilar (Tanvex BioPharma) |
TX-16 |
Phase 1 Clinical |
Tanvex Biopharma |
Colorectal Neoplasms |
Details
|
Bevacizumab biosimilar (Cipla BioTec) |
CBT-124 |
Phase 3 Clinical |
Cipla Gmbh |
Carcinoma, Non-Small-Cell Lung |
Details
|
Bevacizumab biosimilar (Gedeon Richter) |
|
Phase 1 Clinical |
Gedeon Richter Plc |
Neoplasms |
Details
|
Sevacizumab |
TK-001; APX-003; BD-0801; EPI-0030; SIM-BD-0801 |
Phase 2 Clinical |
Epitomics |
Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Wet Macular Degeneration; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration |
Details
|
AAV.7m8-aflibercept (Adverum Biotechnologies) |
ADVM-022 |
Phase 1 Clinical |
Adverum Biotechnologies |
Macular Degeneration |
Details
|
FYB-203 |
FYB-203 |
Phase 3 Clinical |
Formycon |
Macular Degeneration |
Details
|
Recombinant anti-VEGF humanized monoclonal antibody (Jiangsu Aosaikang Pharmaceutical) |
ASK-1202; AMD-B; AK-3008 |
Phase 3 Clinical |
Jiangsu Aosaikang Pharmaceutical Co Ltd |
Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Bevacizumab (Beijing Science Sun) |
K-11; K11 |
Phase 2 Clinical |
Beijing Science Sun Pharmaceutical Co Ltd |
Neoplasms; Glioblastoma; Glioma |
Details
|
Ranibizumab biosimilar (Lupin) |
LUBT-010 |
Phase 3 Clinical |
Lupin Ltd |
Macular Degeneration |
Details
|
Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical) |
CKD-701 |
Phase 3 Clinical |
Chong Kun Dang Pharmaceutical Corp |
Macular Degeneration |
Details
|
Faricimab |
RG-7716; RO-6867461 |
Phase 3 Clinical |
F. Hoffmann-La Roche Ltd |
Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Mellitus; Choroidal Neovascularization; Macular Degeneration |
Details
|
Aflibercept Biosimilar (Boan Biopharma/Luye Pharma) |
LY-09004 |
Phase 3 Clinical |
Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd |
Diabetic macular oedema; Macular Degeneration |
Details
|
Ziv-aflibercept biosimiliar (Boan Biopharma) |
LY-01012 |
Phase 3 Clinical |
Shandong Boan Biotechnology Co Ltd |
Wet Macular Degeneration; Colorectal Neoplasms; Macular Degeneration |
Details
|
Muparfostat sodium |
PI-88 |
Phase 3 Clinical |
Australian National University |
Liver Neoplasms; Solid tumours; Prostatic Neoplasms; Lung Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|